Close Menu

NEW YORK – Molecular diagnostics firm Co-Diagnostics announced Friday that it has entered into a definitive agreement with institutional investors to purchase its stock in a direct offering.

The Salt Lake City, Utah-based firm will sell about 3.5 million shares of its common stock, at $1.45 per share. The offering is expected to close on or about Jan. 28.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.